Heiko Santelmann

Summary

Country: Norway

Publications

  1. ncbi [A new syndrome?]
    Heiko Santelmann
    Tidsskr Nor Laegeforen 127:461. 2007
  2. ncbi Effectiveness of nystatin in polysymptomatic patients. A randomized, double-blind trial with nystatin versus placebo in general practice
    H Santelmann
    Department of General Practice and Community Medicine, University of Oslo, 0317 Oslo, Norway
    Fam Pract 18:258-65. 2001
  3. ncbi Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome
    Heiko Santelmann
    Holistisk Senter, Oslo, Norway
    Eur J Gastroenterol Hepatol 17:21-6. 2005

Detail Information

Publications3

  1. ncbi [A new syndrome?]
    Heiko Santelmann
    Tidsskr Nor Laegeforen 127:461. 2007
  2. ncbi Effectiveness of nystatin in polysymptomatic patients. A randomized, double-blind trial with nystatin versus placebo in general practice
    H Santelmann
    Department of General Practice and Community Medicine, University of Oslo, 0317 Oslo, Norway
    Fam Pract 18:258-65. 2001
    ..Hypersensitivity to fungus proteins and mycotoxins has been proposed as the cause...
  3. ncbi Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome
    Heiko Santelmann
    Holistisk Senter, Oslo, Norway
    Eur J Gastroenterol Hepatol 17:21-6. 2005
    ..But more research is needed before antifungal treatment can be recommended as a first line treatment for IBS...